Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
Company profile
Ticker
ABMD
Exchange
Website
CEO
Michael Minogue
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ABIOMED Holding Company, Inc. • ABIOMED Commercial, LLC • ABIOMED R&D, Inc. • Breethe, Inc. • Precardia, Inc • ABIOMED Australia Pte. Ltd • ABIOMED SARL • Precardia SAS • ABIOMED Europe, GmbH • AIS GmbH ...
IRS number
42743260
ABMD stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Dec 22
Transcripts
ABMD
Earnings call transcript
2023 Q2
1 Nov 22
ABMD
Earnings call transcript
2023 Q1
4 Aug 22
ABMD
Earnings call transcript
2022 Q4
28 Apr 22
ABMD
Earnings call transcript
2022 Q3
4 Feb 22
ABMD
Earnings call transcript
2022 Q2
28 Oct 21
ABMD
Earnings call transcript
2022 Q1
5 Aug 21
ABMD
Earnings call transcript
2021 Q4
29 Apr 21
ABMD
Earnings call transcript
2021 Q3
28 Jan 21
ABMD
Earnings call transcript
2021 Q2
29 Oct 20
ABMD
Earnings call transcript
2021 Q1
6 Aug 20
Latest ownership filings
SC 13G/A
BAILLIE GIFFORD & CO
6 Jan 23
SC 13G
MILLENNIUM MANAGEMENT LLC
29 Dec 22
4
MARTIN P SUTTER
27 Dec 22
4
DOROTHY E PUHY
27 Dec 22
4
Todd A Trapp
27 Dec 22
4
Matthew T. Plano
27 Dec 22
4
MICHAEL R MINOGUE
27 Dec 22
4
Andrew J Greenfield
27 Dec 22
4
Marc A Began
27 Dec 22
4
Paula A Johnson
27 Dec 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 182.34 mm | 182.34 mm | 182.34 mm | 182.34 mm | 182.34 mm | 182.34 mm |
| Cash burn (monthly) | (no burn) | 4.96 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 28.27 mm | n/a | n/a | n/a | n/a |
| Cash remaining | n/a | 154.07 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 31.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
79.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 407 |
| Opened positions | 68 |
| Closed positions | 64 |
| Increased positions | 155 |
| Reduced positions | 143 |
| 13F shares | Current |
|---|---|
| Total value | 6.57 tn |
| Total shares | 35.69 mm |
| Total puts | 126.30 k |
| Total calls | 197.10 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 4.57 mm | $940.22 bn |
| Vanguard | 3.69 mm | $759.71 bn |
| FMR | 3.06 mm | $629.34 bn |
| Capital VII FCPR Sofinnova | 1.69 mm | $93.11 mm |
| ABMD Abiomed | 1.61 mm | $74.15 mm |
| STT State Street | 1.17 mm | $240.87 bn |
| T. Rowe Price | 1.01 mm | $209.18 bn |
| JPM JPMorgan Chase & Co. | 806.51 k | $166.64 bn |
| MCQEF Macquarie | 756.01 k | $155.44 bn |
| Gilder Gagnon Howe & Co | 705.88 k | $145.14 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Dec 22 | Gorder Chris Van | Common Stock, $.01 par value | Grant | Acquire A | No | No | 0 | 7,410 | 0.00 | 0 |
| 22 Dec 22 | Myron L Rolle | Common Stock, $.01 par value | Sale back to company | Dispose D | No | No | 0 | 1,721 | 0.00 | 0 |
| 22 Dec 22 | Paul Thomas | Common Stock, $.01 par value | Sale back to company | Dispose D | No | No | 0 | 6,357 | 0.00 | 0 |
| 22 Dec 22 | Johnson Paula A | Common Stock, $.01 par value | Sale back to company | Dispose D | No | No | 0 | 1,659 | 0.00 | 0 |
| 10 Aug 22 | Jeannine M Rivet | Common Stock, $0.01 par value | Grant | Acquire A | No | No | 0 | 9,285 | 0.00 | 0 |